Resolving drug effects from class effects among drugs for type 2 diabetes mellitus: more support for cardiovascular outcome assessments.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed.

1. Glibenclamide treatment in a Cantú syndrome patient with a pathogenic ABCC9 gain-of-function variant: Initial experience.American journal of medical genetics. Part A · 2019
   Article
2. Should Metformin Remain First-Line Medical Therapy for Patients with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease? An Alternative Approach.Current diabetes reports · 2018
   Review
3. Adenosine Triphosphate-Sensitive Potassium Currents in Heart Disease and Cardioprotection.Cardiac electrophysiology clinics · 2016
   Review
4. Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications.Clinical pharmacology and therapeutics · 2015
   Review
5. Predicting cardiovascular risk in type 2 diabetes: the heterogeneity challenges.Current cardiology reports · 2015
   Review
6. Sulfonylurea in combination with insulin is associated with increased mortality compared with a combination of insulin and metformin in a retrospective Danish nationwide study.Diabetologia · 2015
   Article
7. Bedside-to-Bench Translational Research for Chronic Heart Failure: Creating an Agenda for Clients Who Do Not Meet Trial Enrollment Criteria.Clinical Medicine Insights. Cardiology · 2015
   Review
8. Tuning the electrical properties of the heart by differential trafficking of KATP ion channel complexes.Journal of cell science · 2014
   Article
9. Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus.North American journal of medical sciences · 2014
   Review
10. KATP channels and cardiovascular disease: suddenly a syndrome.Circulation research · 2013
    Review
11. Comment on: Pantalone et al. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Diabetes Care 2010;33:1224-1229.Diabetes care · 2011
    Article
12. PATIENTS TREATED WITH INSULIN AND SULPHONYLUREA ARE AT INCREASED MORTALITY RISK AS COMPARED WITH THOSE TREATED WITH INSULIN PLUS METFORMIN.Acta endocrinologica (Bucharest, Romania : 2005)
    Article

Corrections and comments

• Comment on
  Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study.2011
• Erratum issued

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as